Ultragenyx Q4 revenue $165M, FY $560M; guides 2025 revenue $640-670M

Ultragenyx Pharmaceutical Inc.

2024-FY EPS reported -$6.29 revenue$560,230,000

Q4 2024 total revenue $165M (+29% YoY); FY 2024 total revenue $560M (+29% YoY).
Crysvita FY revenue $410M (+25% YoY); Dojolvi FY revenue $88M (+25% YoY).
FY 2024 net loss $569M ($6.29/diluted share) vs $607M ($8.25) in 2023; cash used ops $414M.
2025 guidance: total revenue $640-670M, Crysvita $460-480M, Dojolvi $90-100M; lower cash ops expected.
PDUFA decision for UX111 gene therapy (Sanfilippo syndrome) expected H2 2025; BLA filing for DTX401 (GSDIa) mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.